- ArcBest: Goldman Sachs maintains neutral rating and raised the target to $100 from $90.
- Ares Management: UBS raised the target to $82 from $68. Maintains buy rating.
- Axonics: Piper Sandler adjusts price target to $82 from $77. Reiterates overweight rating.
- Burlington Stores: Goldman Sachs starts at buy with $183 price target.
- Chemed: RBC Capital Markets maintains outperform rating. PT down 12% to $541.
- Chesapeake Energy: Benchmark Company LLC initiated coverage with a recommendation of buy. PT up 52% to $137.
- Comstock Resources: Piper Sandler raised the recommendation to neutral from underweight. PT up 8.1% to $17.
- Constellation Brands: BMO Capital Markets initiated coverage with a recommendation of outperform. PT up 19% to $290.
- Humana: Morgan Stanley raised the target to $494 from $453. Maintains equal-weight rating.
- Idex: Mizuho Securities Co Ltd raised the target to $205 from $190. Maintains neutral rating.
- Man Group: Numis Securities cut the recommendation to hold from add. PT set to 275 pence.
- Matson: Stifel downgrades to hold from buy. PT up 1.9% to $93.
- Mohawk Industries: RBC Capital Markets maintains underperform rating. PT down 21% to $101.
- Ross Stores: Goldman Sachs reinstated coverage with a recommendation of buy. PT up 24% to $102.
- TJX: Goldman Sachs reinstated coverage with a recommendation of neutral. PT set to $70.
- T. Rowe Price Group: BMO Capital Markets cut the target to $115 from $135. Maintains market perform rating.
- Visteon: Morgan Stanley maintains equal-weight rating. PT up to $107 from $91.
- WW Grainger: Oppenheimer & Co raised the target to $615 from $580. Maintains outperform rating.